Fenofibrate: A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes Mellitus

Global Prevalence of Diabetes

Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · see citing works

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)

Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works

Standards of Medical Care in Diabetes

Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,672 · see citing works

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07037-8 · Cited by 8,247 · see citing works

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works

Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey

Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698 · see citing works

Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

Grundy, S. M., Brewer, H. B., Cleeman, J. I., Smith, S. C., & Lenfant, C. (2004) · Circulation · doi:10.1161/01.cir.0000111245.75752.c6 · Cited by 5,982 · see citing works

Standards of medical care in diabetes—2014

American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572 · see citing works

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

(1998) · PubMed · Cited by 4,290 · see citing works

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,757 · see citing works

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · see citing works

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284 · see citing works

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876 · see citing works

Diabetes and Atherosclerosis

Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,723 · see citing works

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614 · see citing works

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,088 · see citing works

Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · see citing works

Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults

Ford, E. S., Giles, W. H., & Mokdad, A. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2444 · Cited by 1,488 · see citing works

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216 · see citing works

PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.

Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173 · see citing works

Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators

Staels, B., Köenig, W., Habib, A., Merval, R., Lebret, M., Pineda‐Torra, I., Delerive, P., Fadel, A., Chinetti, G., Fruchart, J., et al. (1998) · Nature · doi:10.1038/31701 · Cited by 1,134 · see citing works

The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation

Schoonjans, K., Staels, B., & Auwerx, J. H. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00066-5 · Cited by 1,047 · see citing works

Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial

Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986 · see citing works

Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 916 · see citing works

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04209-4 · Cited by 845 · see citing works

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

Steiner, G. A. (2001) · Cited by 732 · see citing works

Diabetes, Plasma Insulin, and Cardiovascular Disease: Subgroup Analysis From the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT)

Rubins, H. B. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2597 · Cited by 586 · see citing works

Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550 · see citing works

European guidelines on cardiovascular disease prevention in clinical practice<SBT>Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)

Backer, G. D., Ambrosioni, E., Borch‐Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.02.013 · Cited by 508 · see citing works

Peroxisome proliterator-activated receptors, orphans with ligands and functions

Schoonjans, K., Martin, G. V., Staels, B., & Auwerx, J. H. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00006 · Cited by 488 · see citing works

Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels: Subgroup Analyses in the Scandinavian Simvastatin Survival Study

Haffner, S. M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2661 · Cited by 441 · see citing works

CLA-1/SR-BI Is Expressed in Atherosclerotic Lesion Macrophages and Regulated by Activators of Peroxisome Proliferator-Activated Receptors

Chinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.20.2411 · Cited by 428 · see citing works

Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.

Staels, B., Vu-Dac, N., Kosykh, V. A., Saladin, R., Fruchart, J. C., Dallongeville, J., & Auwerx, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117717 · Cited by 410 · see citing works

Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

Vu‐Dac, N., Schoonjans, K., Kosykh, V., Dallongeville, J., Fruchart, J., Staels, B., & Auwerx, J. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118118 · Cited by 397 · see citing works

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387 · see citing works

Effects of Fibrates on Metabolism of Statins in Human Hepatocytes

Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., & Lin, J. H. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.11.1280 · Cited by 323 · see citing works

Dyslipidemia Prevalence, Treatment, and Control in the Multi-Ethnic Study of Atherosclerosis (MESA)

Goff, D. C., Bertoni, A. G., Kramer, H., Bonds, D. E., Blumenthal, R. S., Tsai, M. Y., & Psaty, B. M. (2006) · Circulation · doi:10.1161/circulationaha.105.552737 · Cited by 315 · see citing works

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose

Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313 · see citing works

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)

Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309 · see citing works

Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome

Tenenbaum, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1154 · Cited by 307 · see citing works

Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells

Ylipaasto, P., Klingel, K., Lindberg, A., Otonkoski, T., Kandolf, R., Hovi, T., & Roivainen, M. (2004) · Diabetologia · doi:10.1007/s00125-003-1297-z · Cited by 294 · see citing works

Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy

Grundy, S. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2005 · Cited by 289 · see citing works

Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins

Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 285 · see citing works

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

Athyros, V., Papageorgiou, A., Athyrou, V., Demitriadis, D., & Kontopoulos, A. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1198 · Cited by 277 · see citing works

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.11.004 · Cited by 264 · see citing works

ABC of arterial and venous disease: Vascular complications of diabetes

Donnelly, R. (2000) · BMJ · doi:10.1136/bmj.320.7241.1062 · Cited by 258 · see citing works

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Berthou, L., Duverger, N., Emmanuel, F., Langouët, S., Auwerx, J. H., Guillouzo, A., Fruchart, J., Rubin, E. M., Denèfle, P., Staels, B., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118687 · Cited by 248 · see citing works

Differential Regulation of Lipoprotein Kinetics by Atorvastatin and Fenofibrate in Subjects With the Metabolic Syndrome

Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219 · see citing works

Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia

Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Seo, Y., Choi, I. S., & Shin, E. K. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.052 · Cited by 199 · see citing works

Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy

Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198 · see citing works

Fenofibrate Reduces Plasma Cholesteryl Ester Transfer From HDL to VLDL and Normalizes the Atherogenic, Dense LDL Profile in Combined Hyperlipidemia

Guérin, M., Bruckert, É., Dolphin, P. J., Turpin, G., & Chapman, M. J. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.6.763 · Cited by 194 · see citing works

Gemfibrozil Inhibits CYP2C8-Mediated Cerivastatin Metabolism in Human Liver Microsomes

Wang, J.-S., Neuvonen, M., Wen, X., Backman, J. T., & Neuvonen, P. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1352 · Cited by 189 · see citing works

Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine

Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186 · see citing works

Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia

Koh, K. K., Han, S. H., Quon, M. J., Ahn, J. Y., & Shin, E. K. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1419 · Cited by 182 · see citing works

Beyond Low-Density Lipoprotein

Nesto, R. W. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505060-00005 · Cited by 175 · see citing works

Long-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined Hyperlipidemia

Ellen, R., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 175 · see citing works

Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–α Activators

Zambon, A., Gervois, P. P., Pauletto, P., Fruchart, J., & Staels, B. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000204327.96431.9a · Cited by 162 · see citing works

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

Farnier, M., Freeman, M. W., Macdonell, G., Perevozskaya, I. T., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi231 · Cited by 161 · see citing works

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial — FAT)

Malík, J. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00382-0 · Cited by 149 · see citing works

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

Vega, G. L., Ma, P. T. S., Cater, N. B., Filipchuk, N. G., Meguro, S., García-García, A.-B., & Grundy, S. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00111-5 · Cited by 149 · see citing works

Mechanisms of the Triglyceride- and Cholesterol-Lowering Effect of Fenofibrate in Hyperlipidemic Type 2 Diabetic Patients

Forcheron, F., Cachefo, A., Thevenon, S., Pinteur, C., & Beylot, M. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3486 · Cited by 148 · see citing works

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

Dierkes, J., Westphal, S., & Luley, C. H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02153-4 · Cited by 144 · see citing works

The Reduction of Inflammatory Biomarkers by Statin, Fibrate, and Combination Therapy Among Diabetic Patients With Mixed Dyslipidemia

Muhlestein, J. B., May, H. T., Jensen, J. R., Horne, B. D., Lanman, R. B., Lavasani, F., Wolfert, R. L., Pearson, R. R., Yannicelli, H. D., & Anderson, J. L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.009 · Cited by 140 · see citing works

Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism

Fruchart, J., & Duriez, P. (2006) · Drugs of today · doi:10.1358/dot.2006.42.1.963528 · Cited by 132 · see citing works

Gemfibrozil in the Treatment of Dyslipidemia

Tenkanen, L., Mänttäri, M., Kovanen, P. T., Virkkunen, H., & Manninen, V. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.743 · Cited by 129 · see citing works

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

Frost, R. J., Otto, C., Geiss, H. C., SCHWANDT, P., & Parhofer, K. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01270-4 · Cited by 128 · see citing works

Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles

Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125 · see citing works

Risk of adverse events with fibrates*

Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125 · see citing works

Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.

CASLAKE, M. J., Packard, C. J., Gaw, A., Murray, E. F., Griffin, B. A., Vallance, B. D., & Shepherd, J. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.13.5.702 · Cited by 121 · see citing works

Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator-Activated Receptor α Modulation

Duez, H., Lefebvre, B., Poulain, P., Pineda‐Torra, I., Percevault, F., Luc, G., Peters, J. M., Gonzalez, F. J., Gineste, R., Helleboid, S., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154140.73570.00 · Cited by 120 · see citing works

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.

Haubenwallner, S., Essenburg, A. D., Barnett, B. C., Pape, M. E., Demattos, R. B., Krause, B. R., Minton, L. L., Auerbach, B. J., Newton, R. S., & Leff, T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41090-9 · Cited by 119 · see citing works

Micronised Fenofibrate

Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 113 · see citing works

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

Durrington, P. N., Tuomilehto, J. O., Hamann, A., Kallend, D. G., & Smith, K. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2003.11.012 · Cited by 111 · see citing works

Adequacy of Glycemic, Lipid, and Blood Pressure Management for Patients With Diabetes in a Managed Care Setting

Beaton, S. J., Nag, S. S., Gunter, M. J., Gleeson, J. M., Sajjan, S. S., & Alexander, C. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.694 · Cited by 108 · see citing works

Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia

McKenney, J. M., Farnier, M., Lo, K.-W., Bays, H. E., Perevozkaya, I., Carlson, G. L., Davies, M. J., Mitchel, Y., & Gumbiner, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.072 · Cited by 106 · see citing works

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Martin, P. D., Dane, A. L., Schneck, D. W., & Warwick, M. J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80089-9 · Cited by 103 · see citing works

Lipid-lowering drugs and homocysteine

de Lorgeril, M., Salen, P., Paillard, F., Lacan, P., & Richard, G. J. (1999) · The Lancet · doi:10.1016/s0140-6736(05)77220-2 · Cited by 102 · see citing works

Effects of fenofibrate and gemfibrozil on plasma homocysteine

Westphal, S., Dierkes, J., & Luley, C. H. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05271-5 · Cited by 99 · see citing works

Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans

Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268044 · Cited by 97 · see citing works

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.

Shepherd, J., CASLAKE, M. J., Lorimer, A. R., Vallance, B. D., & Packard, C. J. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.2.162 · Cited by 96 · see citing works

Attenuation of Progression of Insulin Resistance in Patients With Coronary Artery Disease by Bezafibrate

Tenenbaum, A., Fisman, E. Z., Boyko, V., Benderly, M., Tanné, D., Haim, M., Matas, Z., Motro, M., & Behar, S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.737 · Cited by 94 · see citing works

Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers

Pan, W., Gustavson, L. E., Achari, R., Rieser, M. J., Ye, X., Gutterman, C., & Wallin, B. A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008874 · Cited by 91 · see citing works

Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia

Undas, A., Celińska‐Löwenhoff, M., Domagała, T. B., Iwaniec, T., Dropiński, J., Löwenhoff, T., & Szczeklik, A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0067 · Cited by 90 · see citing works

Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance

Okopień, B., Krysiak, R. G., & Herman, Z. S. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1615 · Cited by 88 · see citing works

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

Farnier, M. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.4.441 · Cited by 87 · see citing works

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Georgoula, M., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75078 · Cited by 86 · see citing works

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Filippatos, T. D., Gazi, I. F., Liberopoulos, E. N., Athyros, V. G., Elisaf, M., Tselepis, A. D., & Kiortsis, D. N. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.07.010 · Cited by 84 · see citing works

Short-Term Triglyceride Lowering With Fenofibrate Improves Vasodilator Function in Subjects With Hypertriglyceridemia

Capell, W. H., DeSouza, C. A., Poirier, P., Bell, M. L., Stauffer, B. L., Weil, K. M., Hernandez, T. L., & Eckel, R. H. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000046230.02211.b4 · Cited by 84 · see citing works

Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus

Woodman, R. J., Chew, G. T., & Watts, G. F. (2005) · Drugs · doi:10.2165/00003495-200565010-00003 · Cited by 83 · see citing works

Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X

Idzior−Waluś, B., Sieradzki, J., Rostworowski, W., Zdzienicka, A., Kawalec, E., Wójcik, J., Zarnecki, A. F., & Blane, G. F. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00734.x · Cited by 83 · see citing works

Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy

Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81 · see citing works

Comparison of fluvastatin + fenofibrate combination therapyand fluvastatin monotherapy in the treatment of combined hyperlipidemia,type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial

Derosa, G., Cicero, A. F. G., Bertone, G., Piccinni, M. N., Ciccarelli, L., & Roggeri, D. P. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.10.008 · Cited by 81 · see citing works

Fenofibric Acid, an Active Form of Fenofibrate, Increases Apolipoprotein A-I–Mediated High-Density Lipoprotein Biogenesis by Enhancing Transcription of ATP-Binding Cassette Transporter A1 Gene in a Liver X Receptor–Dependent Manner

Arakawa, R., Tamehiro, N., Nishimaki‐Mogami, T., Ueda, K., & Yokoyama, S. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000163844.07815.c4 · Cited by 79 · see citing works

Fenofibrate Effectively Reduces Remnants, and Small Dense LDL, and Increases HDL Particle Number in Hypertriglyceridemic Men — A Nuclear Magnetic Resonance Study

Ikewaki, K., Tohyama, J., Nakata, Y., Wakikawa, T., Kido, T., & Mochizuki, S. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.278 · Cited by 76 · see citing works

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions

Davidson, M. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.145 · Cited by 76 · see citing works

Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus

Playford, D. A., Watts, G. F., Best, J. D., & Burke, V. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02847-3 · Cited by 75 · see citing works

Untitled work

(1999) · PubMed · Cited by 74 · see citing works

Micronised fenofibrate

Munoz, A., Guichard, J. P., & Reginault, P. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)05375-s · Cited by 73 · see citing works

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation

Sauron, R. É., Wilkins, M. R., Jessent, V., Dubois, A., Maillot, C., & Weil, A. (2006) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp44064 · Cited by 72 · see citing works

Effect of Micronized Fenofibrate and Losartan Combination on Uric Acid Metabolism in Hypertensive Patients with Hyperuricemia

Elisaf, M., Tsimichodimos, V., Bairaktari, E. T., & Siamopoulos, K. C. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199907000-00010 · Cited by 67 · see citing works

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

Koh, K. K., Ahn, J. Y., Han, S. H., Jin, D., Kim, H. S., Lee, K. C., Shin, E. K., & Sakuma, I. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.01.033 · Cited by 66 · see citing works

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

Bissonnette, R., Treacy, E. P., Rozen, R. R., Boucher, B., Cohn, J. S., & Genest, J. J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00584-0 · Cited by 62 · see citing works

Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*

Kosoglou, T., Statkevich, P., Fruchart, J., Pember, L. J. C., Reyderman, L., Cutler, D. L., Guillaume, M., Maxwell, S. E., & Veltri, E. P. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125004277 · Cited by 61 · see citing works

Comparative Effects of Atorvastatin, Simvastatin, and Fenofibrate on Serum Homocysteine Levels in Patients with Primary Hyperlipidemia

Milionis, H. J., Papakostas, J. C., Kakafika, A. I., Chasiotis, G., Seferiadis, K., & Elisaf, M. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003255920 · Cited by 61 · see citing works

AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis.

Jellinger, P. S., Ra, D., Ganda, O. P., Ae, M., Tt, N., Rodbard, H. W., Ja, S., Shepherd, & Da, S. (2000) · PubMed · Cited by 58 · see citing works

Additive Beneficial Effects of Fenofibrate Combined With Candesartan in the Treatment of Hypertriglyceridemic Hypertensive Patients

Koh, K. K., Quon, M. J., Han, S. H., Chung, W., Ahn, J. Y., Kim, J., Lee, Y., & Shin, E. K. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1418 · Cited by 57 · see citing works

Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia

Farnier, M., & Dejager, S. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00606-2 · Cited by 56 · see citing works

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

Kiortsis, D. N., Millionis, H., Bairaktari, E. T., & Elisaf, M. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000213 · Cited by 56 · see citing works

THE LONG-TERM EFFECTS OF THE LIPID-LOWERING AGENT FENOFIBRATE IN HYPERLIPIDEMIC HEART TRANSPLANT RECIPIENTS

Boissonnat, P., Salen, P., Guidollet, J., Ferreea, R., Dueeau, G., Ninet, J., Renaud, S., & de Lorgeril, M. (1994) · Transplantation · doi:10.1097/00007890-199405820-00018 · Cited by 55 · see citing works

Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values

Tsimihodimos, V., Kostoula, A., Kakafika, A. I., Bairaktari, E. T., Tselepis, A. D., Mikhailidis, D. P., & Elisaf, M. (2004) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840400900i105 · Cited by 55 · see citing works

Multicenter Comparison of Micronized Fenofibrate and Simvastatin in Patients with Primary Type IIA or IIB Hyperlipoproteinemia

Steinmetz, A., Schwartz, T., Hehnke, U., & Kaffarnik, H. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199604000-00016 · Cited by 53 · see citing works

Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome

Wysocki, J., Belowski, D., Kalina, M. A., Kochański, L., Okopień, B., & Kalina, Z. (2004) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp42212 · Cited by 52 · see citing works

Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia

McKenney, J. M., Jones, M., & Abby, S. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59157 · Cited by 51 · see citing works

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

Genest, J., Frohlich, J., & Steiner, G. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.12.022 · Cited by 51 · see citing works

Effect of Micronized Fenofibrate on Plasma Lipoprotein Levels and Hemostatic Parameters of Hypertriglyceridemic Patients with Low Levels of High-Density Lipoprotein Cholesterol in the Fed and Fasted State

Genest, J. J., Nh, N., Théroux, P., Davignon, J., & Cohn, J. S. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200001000-00022 · Cited by 49 · see citing works

Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial

Despres, J., Lemieux, I., Salomon, H., & Delaval, D. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00988.x · Cited by 49 · see citing works

Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?

Robins, S. J. (2003) · Current Opinion in Lipidology · doi:10.1097/00041433-200312000-00005 · Cited by 46 · see citing works

Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil)

Farnier, M., Salko, T., Isaacsohn, J. L., Troendle, A. J., Dejager, S., & Gonasun, L. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00885-3 · Cited by 41 · see citing works

Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients

Lemieux, I., Salomon, H., & Després, J. (2003) · Annals of Medicine · doi:10.1080/07853890310011969 · Cited by 40 · see citing works

After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?

Colhoun, H. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67668-4 · Cited by 39 · see citing works

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

Paragh, G., Seres, I., Harangi, M., Balogh, Z., Illyés, L., Boda, J., Szilvássy, Z., & Kovacs, P. L. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70077-0 · Cited by 39 · see citing works

Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: An open Belgian multicenter study

Kornitzer, M., Dramaix, M. W., Vandenbroek, M.-D., Everaert, L., & Gerlinger, C. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)05378-v · Cited by 39 · see citing works

Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide

Kajosaari, L. I., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02158.x · Cited by 37 · see citing works

Fenofibrate or Gemfibrozil for Treatment of Types IIa and IIb Primary Hyperlipoproteinemia: A Randomized, Double-Blind, Crossover Study

Insua, A., Massari, F., Moncalvo, J. J. R., Zanchetta, J., & Insua, A. M. (2002) · Endocrine Practice · doi:10.4158/ep.8.2.96 · Cited by 36 · see citing works

Fenofibrate Monotherapy Induced Rhabdomyolysis

Barker, B. J., Goodenough, R. R., & Falko, J. M. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2482 · Cited by 36 · see citing works

Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease

Packard, K. A., Backes, J. M., Lenz, T. L., Wurdeman, R. L., Destache, C. J., & Hilleman, D. E. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.17.1527.34128 · Cited by 35 · see citing works

Monocyte suppressing action of fenofibrate.

Okopień, B., Kowalski, J., Krysiak, R. G., Łabuzek, K., Stachura-Kułach, A., Kułach, A., Zieliński, M., & Herman, Z. S. (2005) · PubMed · Cited by 34 · see citing works

Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study

Sasaki, J. D., Yamamoto, K., & Ageta, M. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80064-9 · Cited by 34 · see citing works

Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome

Watts, G. F., Ji, J., Chan, D. C., Ooi, E. M. M., Johnson, A. G., Rye, K., & Barrett, P. H. R. (2006) · Clinical Science · doi:10.1042/cs20060072 · Cited by 34 · see citing works

Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia

Kowalski, J., Okopień, B., Madej, A., Zieliński, M., Belowski, D., Kalina, Z., & Herman, Z. S. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41241 · Cited by 34 · see citing works

A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism

Kürşat, S., Alici, T., & Çolak, H. (2005) · Clinical Nephrology · doi:10.5414/cnp64391 · Cited by 33 · see citing works

Effects of fibrates on plasma prothrombotic activity in patients with Type IIb dyslipidemia

Okopień, B., Cwalina, L., Lebek, M., Kowalski, J., Zieliński, M., Wisniewska-Wanat, M., Kalina, Z., & Herman, Z. S. (2001) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp39551 · Cited by 32 · see citing works

Review: Fibrates: therapeutic review

Chapman, M. J. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060010201 · Cited by 31 · see citing works

Effect of Monthly Atorvastatin and Fenofibrate Treatment on Monocyte Chemoattractant Protein-1 Release in Patients with Primary Mixed Dyslipidemia

Okopień, B., Krysiak, R. G., Haberka, M., & Herman, Z. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000156821.50457.32 · Cited by 29 · see citing works

Effect of Colesevelam HCl on Single-Dose Fenofibrate Pharmacokinetics

Jones, M., Baker, B., & Mathew, P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00006 · Cited by 29 · see citing works

Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.

Krempf, M., Rohmer, V., Farnier, M., Issa-Sayegh, M., Corda, C., Sirugue, I., Gerlinger, C., & Masseyeff-Elbaz, M. F. (2000) · PubMed · Cited by 28 · see citing works

The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia

Saklamaz, A., Çömlekçi, A., Artmann, A. T., Uysal, S., Ceylan, C., Alacacıoğlu, A., & Yeşil, S. (2005) · Metabolism · doi:10.1016/j.metabol.2004.12.012 · Cited by 28 · see citing works

Untitled work

(2000) · PubMed · Cited by 28 · see citing works

Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative

Farnier, M. (2003) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200303030-00003 · Cited by 27 · see citing works

The Effects of Multiple Doses of Fenofibrate on the Pharmacokinetics of Pravastatin and Its 3α‐Hydroxy Isomeric Metabolite

Gustavson, L. E., Schweitzer, S. M., Koehne‐Voss, S., Achari, R., Chira, T. O., Esslinger, H., & Yannicelli, H. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278085 · Cited by 27 · see citing works

Rhabdomyolysis with Cardiac Involvement and Acute Renal Failure in a Patient Taking Rosuvastatin and Fenofibrate

Ireland, J. H. E., Eggert, C. H., Arendt, C. J., & Williams, A. W. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-11-200506070-00020 · Cited by 26 · see citing works

Qualitative Effect of Fenofibrate and Quantitative Effect of Atorvastatin on LDL Profile in Combined Hyperlipidemia with dense LDL

Winkler, K. E., Weltzien, P., Friedrich, I., Schmitz, H., Nickell, H.-H., Hauck, P., Hoffmann, M. M., Baumstark, M. W., Wieland, H., & März, W. (2004) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-817970 · Cited by 25 · see citing works

Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control

Tan, C., Chew, L. S., Tai, E. S., Chio, L. F., Lim, H., Loh, L. M., & Shepherd, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00497-4 · Cited by 25 · see citing works

Role of Lp A-I and Lp A-I/A-II in Cholesteryl Ester Transfer Protein–Mediated Neutral Lipid Transfer

McPherson, R., Agnani, G., Lau, P., Fruchart, J., Edgar, A. D., & Marcel, Y. L. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.11.1340 · Cited by 25 · see citing works

Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia

Kowalski, J., Belowski, D., Okopień, B., Madej, A., Zieliński, M., Kalina, Z., & Herman, Z. S. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0581-7 · Cited by 25 · see citing works

Effectiveness and Tolerability of 12-Week Treatment with Micronised Fenofibrate 200mg in a Drug-Monitoring Programme Involving 9884 Patients with Dyslipidaemia

ssler, K. U. K., Schmitz, H., & Bach, G. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199815030-00004 · Cited by 25 · see citing works

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects

Gustavson, L. E., Schweitzer, S. M., Burt, D. A., Achari, R., Rieser, M. J., Edeki, T. I., Chira, T. O., Yannicelli, H. D., & Kelly, M. T. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.009 · Cited by 23 · see citing works

Normalization of metabolic syndrome using fenofibrate, metformin or their combination

Nieuwdorp, M., Stroes, E. S. G., Kastelein, J. J. P., & Fenofibrate/Metformin study group (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00668.x · Cited by 23 · see citing works

Fenofibrate improves microcirculation in patients with hyperlipidemia.

Haak, T., Haak, E., Kusterer, K., Weber, A., Kohleisen, M., & Usadel, K.-H. (1998) · PubMed · Cited by 23 · see citing works

The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.

Yeşilbursa, D., Serdar, A., Saltan, Y., Serdar, Z., Heper, Y., Güçlü, S., & Cordan, J. (2005) · PubMed · Cited by 22 · see citing works

Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia

Ye, P., Li, J., Su, G., & Zhang, C. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.01.023 · Cited by 21 · see citing works

The Role of Fibrates in a Statin World

Bloomfield, H. E. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.715 · Cited by 21 · see citing works

Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone

Ledl, M., Hohenecker, J., Francesconi, C. M., Roots, I., Bauer, M. F., & Roden, M. (2005) · Diabetologia · doi:10.1007/s00125-005-1919-8 · Cited by 21 · see citing works

Simvastatin, Fenofibrate, and Rhabdomyolysis

Jacob, S. S., Jacob, S., Williams, C. D., & Deeg, M. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1258 · Cited by 20 · see citing works

Efficacy and tolerability of a “suprabioavailable” formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials

Ramjattan, B., Callaghan, D. J. G., & Theiss, U. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80022-4 · Cited by 18 · see citing works

Effect of Fenofibrate on Lipoprotein(a) in Hypertriglyceridemic Patients

Ko, H. S., Kim, C. J., & Ryu, W. S. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000175875.48167.c7 · Cited by 18 · see citing works

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

Yang, T., Chen, M., Xia, X., Bai-lin, L., & Li, Y. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0095-6 · Cited by 18 · see citing works

Combined Treatment with Fibrates and Small Doses of Atorvastatin in Patients with Mixed Hyperlipidemia

Liamis, G. L., Kakafika, A. I., Bairaktari, E. T., Miltiadous, G. A., Tsimihodimos, V., Goudevenos, J. A., Achimastos, A. D., & Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000372 · Cited by 18 · see citing works

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients

Çoban, E., Özdoğan, M., Yazicioglu, G., & Sarı, R. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00428.x · Cited by 17 · see citing works

Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

Rašlová, K., Dubovská, D., Mongiellová, V., & Trnovec, T. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050257 · Cited by 17 · see citing works

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

Cavallero, E., Dachet, C., Assadollahi, F., Martin, C., Navarro, N., Ansquer, J.-C., Corda, C., Foucher, C., Juhan-Vague, I., & JACOTOT, B. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00321-0 · Cited by 17 · see citing works

Effect of a single daily dose treatment of fenofibrate on plasma lipoproteins in hyperlipoproteinaemia IIb

Bertolini, S., Elicio, N., Daga, A., Degl’Innocenti, M. L., Balestreri, R., Fusi, M. G., Ramusino, A. M. C., & Carozzi, A. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf01061412 · Cited by 15 · see citing works

Comparison of Micronized Fenofibrate and Pravastatin in Patients With Primary Hyperlipidemia

Ducobu, J., Vanhaelst, L., & Salomon, H. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200301000-00008 · Cited by 13 · see citing works

Efficacy, Safety and Tolerability of???Combined Low-Dose Simvastatin-Fenofibrate Treatment in Primary Mixed Hyperlipidaemia

Stefanutti, C., Bucci, A., Giacomo, S. D., Fraone, N., Pace, A., Mareri, M., Musca, A., & Mammarella, A. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424080-00005 · Cited by 13 · see citing works

Management of Diabetic Dyslipidemia

Khera, A., & McGuire, D. K. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505020-00002 · Cited by 12 · see citing works

Effect of Fenofibrate on Uric Acid Metabolism in Japanese Hyperlipidemic Patients

Noguchi, Y., Tatsuno, I., Suyama, K., Shibata, T., Yoshida, T., Otsuka, Y., Fuse, M., Takeo, C., & Saitō, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.335 · Cited by 12 · see citing works

Fenofibrate-induced myopathy.

Ghosh, B., Sengupta, S., Bhattacharjee, B., Majumder, A., & Sarkar, S. B. (2004) · PubMed · Cited by 11 · see citing works

A New Perspective in the Treatment of Dyslipidemia

Steiner, G. A. (2005) · Treatments in Endocrinology · doi:10.2165/00024677-200504050-00004 · Cited by 10 · see citing works

A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.

Zhu, J., & Ye, P. (2003) · PubMed · Cited by 5 · see citing works

Untitled work

Laffel (1999) · doi:10.1002/(sici)1520-7560(199911/12)15:6

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463 · see citing works

The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

Tsume, Y., Mudie, D. M., Langguth, P., Amidon, G. E., & Amidon, G. L. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.01.009 · Cited by 352 · see citing works

Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: Comparison with Captopril

Susalit, E., Agus, N., Effendi, I., Tjandrawinata, R. R., Nofiarny, D., Perrinjaquet-Moccetti, T., & Verbruggen, M. A. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.08.016 · Cited by 247 · see citing works

Room‐Temperature Decarboxylative Alkynylation of Carboxylic Acids Using Photoredox Catalysis and EBX Reagents

Vaillant, F. L., Courant, T., & Waser, J. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505111 · Cited by 224 · see citing works

Disorders of lipid metabolism. Clinical Guidelines 2023

Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 260 · see citing works

Phenols in Pharmaceuticals: Analysis of a Recurring Motif

Scott, K. A., Cox, P. B., & Njardarson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00223 · Cited by 217 · see citing works

A review: benefit and bioactive properties of olive (Olea europaea L.) leaves

Özcan, M. M., & Matthäus, B. (2016) · European Food Research and Technology · doi:10.1007/s00217-016-2726-9 · Cited by 177 · see citing works

Fenofibrate

McKeage, K., & Keating, G. M. (2011) · Drugs · doi:10.2165/11208090-000000000-00000 · Cited by 175 · see citing works

Management of diabetic nephropathy: Recent progress and future perspective

Ahmad, J. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.02.008 · Cited by 157 · see citing works

Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARα

Chen, Q., Qiu, F., Zhou, K., Matlock, H. G., Takahashi, Y., Rajala, R. V. S., Yang, Y., Pearsall, E., & Ma, J. (2017) · Diabetes · doi:10.2337/db16-1246 · Cited by 152 · see citing works

Approaches to prevention of cardiovascular complications and events in diabetes mellitus

Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139 · see citing works

The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development

Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139 · see citing works

Polyphenols benefits of olive leaf (Olea europaea L) to human health.

Vogel, P., Machado, I. K., Garavaglia, J., Zani, V. T., de Souza, D., & Bosco, S. M. D. (2014) · PubMed · doi:10.3305/nh.2015.31.3.8400 · Cited by 123 · see citing works

Fenofibrate: treatment of hyperlipidemia and beyond

Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1319 · Cited by 111 · see citing works

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma

Scarisbrick, J. J., Morris, S., Azurdia, R. M., Illidge, T., PARRY, E. J., GRAHAM-BROWN, R. A. C., Cowan, R. A., Gallop‐Evans, E., Wachsmuth, R. C., Eagle, M., et al. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12042 · Cited by 102 · see citing works

Antidepressant‐like effects of fenofibrate in mice via the hippocampal brain‐derived neurotrophic factor signalling pathway

Jiang, B., Wang, Y., Wang, H., Song, L., Huang, C., Zhu, Q., Wu, F., & Zhang, W. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13668 · Cited by 96 · see citing works

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94 · see citing works

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations

Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 85 · see citing works

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Konrad, R. J., Troutt, J. S., & Cao, G. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-38 · Cited by 72 · see citing works

Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor- κ B and transforming growth factor- β 1/Smad3 in diabetic nephropathy

Li, L., Emmett, N. L., Mann, D. R., & Zhao, X. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009218 · Cited by 72 · see citing works

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Troutt, J. S., Alborn, W. E., Cao, G., & Konrad, R. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m000620 · Cited by 71 · see citing works

Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus

Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A. C., & Taskinen, M. R. (2007) · Diabetologia · doi:10.1007/s00125-007-0751-8 · Cited by 68 · see citing works

Fenofibrate and the kidney: an overview

Kostapanos, M. S., Florentin, M., & Elisaf, M. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12068 · Cited by 66 · see citing works

Room‐Temperature Decarboxylative Alkynylation of Carboxylic Acids Using Photoredox Catalysis and EBX Reagents

Vaillant, F. L., Courant, T., & Waser, J. (2015) · Angewandte Chemie · doi:10.1002/ange.201505111 · Cited by 64 · see citing works

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

Farnier, M. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3390 · Cited by 64 · see citing works

Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate

Taskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.178228 · Cited by 63 · see citing works

Neuroprotective effect of PPAR alpha and gamma agonists in a mouse model of amyloidogenesis through modulation of the Wnt/beta catenin pathway via targeting alpha- and beta-secretases

Assaf, N., El-Shamarka, M. E.-S., Salem, N. A., Khadrawy, Y. A., & Sayed, N. S. E. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109793 · Cited by 59 · see citing works

Fenofibrate-associated nephrotoxicity: A review of current evidence

Attridge, R. L., Frei, C. R., Ryan, L., Koeller, J. M., & Linn, W. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120131 · Cited by 57 · see citing works

Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL

Fan, A., Wu, X., Wu, H., Li, L., Huang, R., Zhu, Y., Qiu, Y., Fu, J., Ren, J., & Zhu, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085337 · Cited by 56 · see citing works

Controllable Single and Double Difluoromethylene Insertions into C–Cu Bonds: Copper-Mediated Tetrafluoroethylation and Hexafluoropropylation of Aryl Iodides with TMSCF2H and TMSCF2Br

Wang, X., Pan, S., Luo, Q., Wang, Q., Ni, C., & Hu, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03104 · Cited by 55 · see citing works

Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?

Tufano, M., & Pinna, G. (2020) · Molecules · doi:10.3390/molecules25051062 · Cited by 55 · see citing works

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study

Davidson, M. H., Rooney, M. W., Drucker, J. L., Griffin, H. E., Oosman, S., & Beckert, M. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.12.007 · Cited by 52 · see citing works

After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.

Sacks, F. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.073 · Cited by 50 · see citing works

Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia

Pruski, M., Krysiak, R. G., & Okopień, B. (2009) · Diabetes Care · doi:10.2337/dc08-2335 · Cited by 48 · see citing works

High Density Lipoprotein Structural Changes and Drug Response in Lipidomic Profiles following the Long-Term Fenofibrate Therapy in the FIELD Substudy

Yetukuri, L., Huopaniemi, I., Koivuniemi, A., Maranghi, M., Hiukka, A., Nygrén, H., Samuel Kaski, A., Taskinen, M., Vattulainen, I., Jauhiainen, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023589 · Cited by 47 · see citing works

In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine

Devraj, R., Williams, H. D., Warren, D. B., Kazi, M., Porter, C. J. H., & Pouton, C. W. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.036 · Cited by 46 · see citing works

Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states

Pérez‐Martínez, P., Corella, D., Shen, J., Arnett, D. K., Yiannakouris, N., Tai, E. S., Orho‐Melander, M., Tucker, K. L., Tsai, M. Y., Straka, R. J., et al. (2008) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26363 · Cited by 46 · see citing works

Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study

Miselli, M. A., Nora, E. D., Passaro, A., Tomasi, F., & Zuliani, G. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0135-6 · Cited by 45 · see citing works

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 45 · see citing works

Serum uric acid: Marker for atherosclerosis as it is positively associated with “atherogenic index of plasma”

Baliarsingh, S., Sharma, N., & Mukherjee, R. (2012) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.732580 · Cited by 44 · see citing works

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

Kukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Balakhonova, T. V., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 48 · see citing works

Fenofibrate and metabolic syndrome

T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic &amp; Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40 · see citing works

A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery

Sjogren, A.-K. M., Breitholtz, K., Ahlberg, E., Milton, L., Forsgard, M., Persson, M., Stahl, S. H., Wilmer, M. J. G., & Hornberg, J. J. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2284-y · Cited by 40 · see citing works

Fenofibric Acid

Yang, L. P. H., & Keating, G. M. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/11203920-000000000-00000 · Cited by 39 · see citing works

Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy

Farnier, M., Ducobu, J., & Bryniarski, L. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.05.005 · Cited by 39 · see citing works

Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs

Kim, K. S., Jin, S. G., Mustapha, O., Yousaf, A. M., Kim, D. W., Kim, Y. H., Kim, J. O., Yong, C. S., Woo, J. S., & Choi, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.05.059 · Cited by 39 · see citing works

Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study

Wojczynski, M. K., Gao, G., Borecki, I. B., Hopkins, P. N., Parnell, L. D., Lai, C., Ordovás, J. M., Chung, B. H., & Arnett, D. K. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p001834 · Cited by 38 · see citing works

Cobalt-catalyzed acylation-reactions of (hetero)arylzinc pivalates with thiopyridyl ester derivatives

Lutter, F. H., Grokenberger, L., Hofmayer, M. S., & Knochel, P. (2019) · Chemical Science · doi:10.1039/c9sc01817d · Cited by 36 · see citing works

Effect of Fenofibrate Medication on Renal Function

Kim, S., Ko, K., Park, S., Lee, D. R., & Lee, J. (2017) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2017.38.4.192 · Cited by 34 · see citing works

The dual PPARα/γ agonist tesaglitazar blocks progression of pre‐existing atherosclerosis in APOE*3Leiden.CETP transgenic mice

van der Hoorn, J., Jukema, J. W., Havekes, L. M., Lundholm, E., Camejo, G., Rensen, P. C. N., & Princen, H. M. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00109.x · Cited by 33 · see citing works

Photocatalytic Keto- and Amino-Trifluoromethylation of Alkenes

Wang, Z., Lin, J., & Xiao, J. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c00447 · Cited by 30 · see citing works

Small Heterodimer Partner-Targeting Therapy Inhibits Systemic Inflammatory Responses through Mitochondrial Uncoupling Protein 2

Yang, C., Yuk, J., Kim, J.-J., Hwang, J. H., Lee, C., Kim, J., Oh, G. T., Choi, H., & Jo, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063435 · Cited by 30 · see citing works

Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study

Farnier, M., Steinmetz, A., Retterstøl, K., & Császár, A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.02.006 · Cited by 30 · see citing works

Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model

Chang, N. W., Tsai, M.-H., Lin, C., Hsu, H. T., Chu, P., Yeh, C., Chiu, C., & Yeh, K.-T. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.11.002 · Cited by 30 · see citing works

The role of pioglitazone in modifying the atherogenic lipoprotein profile

Markolf Hanefeld, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01048.x · Cited by 30 · see citing works

PCSK 9 in diabetic kidney disease

Elewa, U., Fernández‐Fernández, B., Mahíllo, I., Martín-Cleary, C., Sanz, A. B., Sánchez-Niño, M. D., & Ortíz, A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12661 · Cited by 30 · see citing works

Unraveling the Crosstalk between Lipids and NADPH Oxidases in Diabetic Kidney Disease

Njeim, R., Alkhansa, S., & Fornoni, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051360 · Cited by 29 · see citing works

Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors

Gerich, J. E. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80028-7 · Cited by 29 · see citing works

Hepatotoxicity of Cardiovascular and Antidiabetic Drugs

Marzio, D. H., & Navarro, V. J. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-387817-5.00029-7 · Cited by 28 · see citing works

Carotid Intima-Media Thickness Testing as an Asymptomatic Cardiovascular Disease Identifier and Method for Making Therapeutic Decisions

Doneen, A. L., & Bale, B. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.03.2645 · Cited by 28 · see citing works

Targeting lipid metabolism in multiple myeloma cells: Rational development of a synergistic strategy with proteasome inhibitors

Xu, G., Huang, S., Peng, J., Gao, X., Li, M., Yu, S., Liu, Z., Qie, P., Wang, Y., Yu, S., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15653 · Cited by 27 · see citing works

Solubility of Fenofibrate in Different Binary Solvents: Experimental Data and Results of Thermodynamic Modeling

Sun, H., Liu, B., Liu, P., Zhang, J., & Wang, Y. (2016) · Journal of Chemical & Engineering Data · doi:10.1021/acs.jced.6b00268 · Cited by 26 · see citing works

Circulating Levels of Proprotein Convertase Subtilisin Kexin Type 9 are Elevated by Fibrate Therapy

Sahebkar, A. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000025 · Cited by 25 · see citing works

Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics

Highlander, P. D., & Shaw, G. P. (2009) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944709354305 · Cited by 25 · see citing works

Emerging Pharmacotherapies for Diabetic Macular Edema

Javey, G., Schwartz, S. G., & Flynn, H. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/548732 · Cited by 25 · see citing works

Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?

Schindler, C. (2007) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944707082662 · Cited by 25 · see citing works

Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg

Wi, J. H., Kim, J., Park, S., Kang, S., Jang, Y., Chung, N., Shim, W., Cho, S.-Y., & Lee, S. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.068 · Cited by 23 · see citing works

Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

Attridge, R. L., Linn, W. D., Ryan, L., Koeller, J. M., & Frei, C. R. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.008 · Cited by 23 · see citing works

Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

Krysiak, R. G., Stachura-Kułach, A., & Okopień, B. (2010) · Pharmacological Reports · doi:10.1016/s1734-1140(10)70249-8 · Cited by 23 · see citing works

Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome

The Study Investigators, Ansquer, J.-C., Bekaert, I., Guy, M., Markolf Hanefeld, E., & Simon, A. C. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256580 · Cited by 23 · see citing works

Prevention and management of chronic kidney disease in type 2 diabetes

Chadban, S. J., Howell, M., Twigg, S. M., Thomas, M. C., Jerums, G., Cass, A., Campbell, D. A., Nicholls, K., Tong, A., Mangos, G., et al. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01240.x · Cited by 22 · see citing works

Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs

Lucas, A. T., Herity, L. B., Kornblum, Z. A., Madden, A. J., Gabizón, A., Kabanov, A. V., Ajamie, R. T., Bender, D. M., Kulanthaivel, P., Sánchez-Félix, M., et al. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.04.079 · Cited by 21 · see citing works

Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status

Feitosa, M. F., An, P., Ordovás, J. M., Ketkar, S., Hopkins, P. N., Straka, R. J., Arnett, D. K., & Borecki, I. B. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.01.011 · Cited by 20 · see citing works

Acute cholestatic hepatitis induced by fenofibrate

Hajdù, D., Aiglová, K., Vinklerová, I., & Urbánek, K. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01029.x · Cited by 20 · see citing works

Optimization and evaluation of lyophilized fenofibrate nanoparticles with enhanced oral bioavailability and efficacy

Ibrahim, A. H., Ibrahim, H. M., Ismael, H. R., & Samy, A. M. (2017) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1295065 · Cited by 19 · see citing works

NADPH Oxidase 3: Beyond the Inner Ear

Herb, M. (2024) · Antioxidants · doi:10.3390/antiox13020219 · Cited by 18 · see citing works

Kallistatin leads to cognition impairment via downregulating glutamine synthetase

Long, Y., Zhao, Z., Xie, W., Shi, J., Yang, F., Zhu, D., Jiang, P., Tang, Q., Zhou, T., Jiang, B., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107145 · Cited by 18 · see citing works

Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants

Dong, Y., Steffen, B. T., Cao, J., Tsai, A. K., Ordovás, J. M., Straka, R. J., Zhou, X., Kabagambe, E. K., Hanson, N. Q., Arnett, D. K., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.11.022 · Cited by 18 · see citing works

Fenofibrate for Cardiovascular Disease Prevention in Metabolic Syndrome and Type 2 Diabetes Mellitus

Steiner, G. A. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.072 · Cited by 18 · see citing works

Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia

Ali, Y. S., Linton, M. F., & Fazio, S. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f5ff98 · Cited by 17 · see citing works

Fenofibrate, an Anti-Dyslipidemia Drug, Elicits the Dilation of Isolated Porcine Retinal Arterioles: Role of Nitric Oxide and AMP-Activated Protein Kinase

Omae, T., Nagaoka, T., Tanano, I., Kamiya, T., & Yoshida, A. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8841 · Cited by 16 · see citing works

Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics

Arutyunov, G. P., Boytsov, S. A., Voyevoda, M. I., Gurevich, V. S., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Sergiyenko, I. V., Shestakova, M. V., Aliyeva, A. S., et al. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-2-282-288 · Cited by 16 · see citing works

Drug Gene-Set Analysis Identifies Established and Emerging Therapeutic MechanismsPreprint

Bell, N. Y., Uffelmann, E., van Walree, E. S., Schipper, M., Heilbron, K., de Leeuw, C., & Posthuma, D. (2022) · medRxiv · doi:10.1101/2022.09.06.22279660 · Cited by 16 · see citing works

Quality by design assisted high‐performance liquid chromatography parameters for simultaneous estimation of simvastatin and fenofibrate

Rajput, G., Patel, P., Singh, D., Asati, V., & Kurmi, B. D. (2022) · Separation Science Plus · doi:10.1002/sscp.202200078 · Cited by 15 · see citing works

Fenofibrate inhibits intestinal Cl−secretion by blocking basolateral KCNQ1 K+channels

Bajwa, P. J., Alioua, A., Lee, J. W., Straus, D. S., Toro, L., & Lytle, C. Y. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00234.2007 · Cited by 15 · see citing works

Ph3P═O-Catalyzed Reductive Deoxygenation of Alcohols

Li, Q., Sun, Y., Fu, M.-X., Lin, J., & Xiao, J. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c01847 · Cited by 14 · see citing works

Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials

Godfrey, A. R., DiGiacinto, J. L., & Davis, M. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.047 · Cited by 14 · see citing works

Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency

Krysiak, R. G., Gilowska, M., & Okopień, B. (2016) · Clinical Cardiology · doi:10.1002/clc.22593 · Cited by 13 · see citing works

Correction of hypertriglyceridemia in order to reduce the residual risk in atherosclerosis-related diseases. Expert Council Opinion

Arutyunov, G. P., Boytsov, S. A., Voevoda, M. I., Drapkina, O. M., Kukharchuk, V. V., Ai, M., Shestakova, M. V., Gurevich, V. S., Сергиенко, И. В., Alieva, A. S., et al. (2019) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2019-9-44-51 · Cited by 13 · see citing works

Pharmacotherapy for diabetic retinopathy

Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902910092 · Cited by 12 · see citing works

Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice

Pan, S.-Y., Zhu, P., Zhou, S., Zhang, Y., Wang, X., Sun, N., Chu, Z.-S., Yu, Z., & Ko, K. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s73544 · Cited by 12 · see citing works

Fenofibrate increases neuronal vasoconstrictor response in mesenteric arteries from diabetic rats: Role of noradrenaline, neuronal nitric oxide and calcitonin gene-related peptide

del Campo, L., Blanco‐Rivero, J., & Balfagón, G. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.056 · Cited by 12 · see citing works

Different Effects of Fenofibrate on Metabolic and Cardiovascular Risk Factors in Mixed Dyslipidemic Women With Normal Thyroid Function and Subclinical Hypothyroidism

Krysiak, R. G., Gilowski, W., Szkróbka, W., & Okopień, B. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12095 · Cited by 12 · see citing works

Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events

Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12 · see citing works

Chemical and protein structural basis for biological crosstalk between PPARα and COX enzymes

Cleves, A. E., & Jain, A. N. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9815-2 · Cited by 11 · see citing works

Effect of Bezafibrate on Monocyte Cytokine Release and Systemic Inflammation in Patients With Impaired Fasting Glucose

Krysiak, R. G., & Okopień, B. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010382914 · Cited by 11 · see citing works

Fenofibrate in the treatment of dyslipidemia associated with HIV infection

Samineni, D., & Fichtenbaum, C. J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.504715 · Cited by 11 · see citing works

Therapeutic Potential of Topical Fenofibrate Eyedrops in Diabetic Retinopathy and AMD Rat Models

Shen, Y. G. W. (2014) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000347 · Cited by 11 · see citing works

Summarizing the FIELD study: lessons from a ‘negative' trial

Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.850075 · Cited by 10 · see citing works

A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice

Chu, Z.-S., Yu, Z., Pan, S.-Y., Jia, Z., Wang, X.-Y., Zhang, Y., Zhu, P., Wang, X.-J., & Ko, K. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0097-z · Cited by 10 · see citing works

Fenofibrate: a guide to its use in dyslipidaemia

Keating, G. M., & McKeage, K. (2012) · Drugs & Therapy Perspectives · doi:10.2165/11608570-000000000-00000 · Cited by 1 · see citing works

Micronized Fenofibrate: A Useful Choice for the Correction of Dyslipidemia in Metabolic Syndrome and Type 2 Diabetes

Grieve, S. M., Ansquer, J.-C., & KEECH, A. C. (2006) · Future Cardiology · doi:10.2217/14796678.2.6.635

Fenofibrate: treatment of hyperlipidemia and beyond

Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1319 · Cited by 111 · see citing works

Fenofibrate: Metabolic and Pleiotropic Effects

Tsimihodimos, V., Miltiadous, G. A., Daskalopoulou, S. S., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 74 · see citing works

Micronised Fenofibrate

Keating, G. M., & Ormrod, D. J. (2002) · Drugs · doi:10.2165/00003495-200262130-00013 · Cited by 113 · see citing works